{"id":19168,"date":"2021-03-15T10:07:25","date_gmt":"2021-03-15T09:07:25","guid":{"rendered":"https:\/\/www.hollandbio.nl\/?p=19168"},"modified":"2021-03-15T10:07:26","modified_gmt":"2021-03-15T09:07:26","slug":"interna-technologies-awarded-e-2-7m-clinical-innovation-credit-from-dutch-government","status":"publish","type":"post","link":"https:\/\/www.hollandbio.nl\/en\/nieuws\/interna-technologies-awarded-e-2-7m-clinical-innovation-credit-from-dutch-government\/","title":{"rendered":"InteRNA Technologies Awarded \u20ac 2.7M Clinical Innovation Credit from Dutch Government"},"content":{"rendered":"\n

InteRNA Technologies<\/a> a clinical-stage biotech company developing microRNA (miRNA)-based therapeutics with a focus on cancer, today announced that it was awarded a Clinical Innovation Credit of \u20ac 2.7 Million from the Dutch government. This award will support the clinical validation of the Company\u2019s lead candidate, INT-1B3, for the treatment of solid tumors. The funding is granted by the \u2018Rijksdienst voor Ondernemend Nederland\u2019\/The Netherlands Enterprise Agency (RVO), an agency of the Dutch Ministry of Economic Affairs and Climate Policy.<\/p>\n\n\n\n

The Clinical Innovation Credit aims to fund Dutch clinical development projects that have a highly innovative character and strong commercial potential. The projects have to be focused on the development of new products, processes or services.<\/p>\n\n\n\n

\u201cThe support we receive from our government through this funding recognizes the innovative character and commercial outlook of our lead program, both key prerequisites to qualify for the awarded credit,\u201d said Roel Schaapveld, CEO of InteRNA Technologies. \u201cThe Clinical Innovation Credit complements our recently closed Series B round, enabling us to execute our clinical development plan for INT-1B3 towards the treatment of more advanced stages of solid tumors for which there currently are no adequate treatments available.\u201d<\/p>\n\n\n\n

Recently, InteRNA announced<\/a> the dosing of the first patient in the first-in-human trial for INT-1B3, which is conducted in several clinical study centers located in the Netherlands and Belgium. Topline results from the dose escalation part of the study are expected by the end of 2021.<\/p>\n\n\n\n

Source: InteRNA (Press Release<\/a>)<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"

InteRNA Technologies a clinical-stage biotech company developing microRNA (miRNA)-based therapeutics with a focus on cancer, today announced that it was awarded a Clinical Innovation Credit of \u20ac 2.7 Million from the Dutch government. This award will support the clinical validation of the Company\u2019s lead candidate, INT-1B3, for the treatment of solid tumors. The funding is […]<\/p>\n","protected":false},"author":16,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[43],"tags":[],"class_list":["post-19168","post","type-post","status-publish","format-standard","hentry","category-innovatieklimaat"],"acf":[],"yoast_head":"\nInteRNA Technologies Awarded \u20ac 2.7M Clinical Innovation Credit from Dutch Government - hollandbio<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/interna-technologies-awarded-e-2-7m-clinical-innovation-credit-from-dutch-government\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"InteRNA Technologies Awarded \u20ac 2.7M Clinical Innovation Credit from Dutch Government - hollandbio\" \/>\n<meta property=\"og:description\" content=\"InteRNA Technologies a clinical-stage biotech company developing microRNA (miRNA)-based therapeutics with a focus on cancer, today announced that it was awarded a Clinical Innovation Credit of \u20ac 2.7 Million from the Dutch government. This award will support the clinical validation of the Company\u2019s lead candidate, INT-1B3, for the treatment of solid tumors. The funding is […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/interna-technologies-awarded-e-2-7m-clinical-innovation-credit-from-dutch-government\/\" \/>\n<meta property=\"og:site_name\" content=\"hollandbio\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-15T09:07:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-03-15T09:07:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2025\/01\/hb-opengraph_illu.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"HollandBIO\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@hollandbio\" \/>\n<meta name=\"twitter:site\" content=\"@hollandbio\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"HollandBIO\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/interna-technologies-awarded-e-2-7m-clinical-innovation-credit-from-dutch-government\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/interna-technologies-awarded-e-2-7m-clinical-innovation-credit-from-dutch-government\\\/\"},\"author\":{\"name\":\"HollandBIO\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/person\\\/48824449f08e494bb7ea02e1ff5dd6ea\"},\"headline\":\"InteRNA Technologies Awarded \u20ac 2.7M Clinical Innovation Credit from Dutch Government\",\"datePublished\":\"2021-03-15T09:07:25+00:00\",\"dateModified\":\"2021-03-15T09:07:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/interna-technologies-awarded-e-2-7m-clinical-innovation-credit-from-dutch-government\\\/\"},\"wordCount\":254,\"publisher\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\"},\"articleSection\":[\"Innovatieklimaat\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/interna-technologies-awarded-e-2-7m-clinical-innovation-credit-from-dutch-government\\\/\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/interna-technologies-awarded-e-2-7m-clinical-innovation-credit-from-dutch-government\\\/\",\"name\":\"InteRNA Technologies Awarded \u20ac 2.7M Clinical Innovation Credit from Dutch Government - hollandbio\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#website\"},\"datePublished\":\"2021-03-15T09:07:25+00:00\",\"dateModified\":\"2021-03-15T09:07:26+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/interna-technologies-awarded-e-2-7m-clinical-innovation-credit-from-dutch-government\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/interna-technologies-awarded-e-2-7m-clinical-innovation-credit-from-dutch-government\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/interna-technologies-awarded-e-2-7m-clinical-innovation-credit-from-dutch-government\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"InteRNA Technologies Awarded \u20ac 2.7M Clinical Innovation Credit from Dutch Government\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\",\"name\":\"hollandbio\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\",\"name\":\"hollandbio\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/HollandBIO_logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.hollandbio.nl\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/HollandBIO_logo.svg\",\"width\":218.664,\"height\":29.659,\"caption\":\"hollandbio\"},\"image\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/hollandbio\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/hollandbio\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/person\\\/48824449f08e494bb7ea02e1ff5dd6ea\",\"name\":\"HollandBIO\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"InteRNA Technologies Awarded \u20ac 2.7M Clinical Innovation Credit from Dutch Government - hollandbio","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.hollandbio.nl\/en\/nieuws\/interna-technologies-awarded-e-2-7m-clinical-innovation-credit-from-dutch-government\/","og_locale":"en_US","og_type":"article","og_title":"InteRNA Technologies Awarded \u20ac 2.7M Clinical Innovation Credit from Dutch Government - hollandbio","og_description":"InteRNA Technologies a clinical-stage biotech company developing microRNA (miRNA)-based therapeutics with a focus on cancer, today announced that it was awarded a Clinical Innovation Credit of \u20ac 2.7 Million from the Dutch government. This award will support the clinical validation of the Company\u2019s lead candidate, INT-1B3, for the treatment of solid tumors. The funding is […]","og_url":"https:\/\/www.hollandbio.nl\/en\/nieuws\/interna-technologies-awarded-e-2-7m-clinical-innovation-credit-from-dutch-government\/","og_site_name":"hollandbio","article_published_time":"2021-03-15T09:07:25+00:00","article_modified_time":"2021-03-15T09:07:26+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2025\/01\/hb-opengraph_illu.png","type":"image\/png"}],"author":"HollandBIO","twitter_card":"summary_large_image","twitter_creator":"@hollandbio","twitter_site":"@hollandbio","twitter_misc":{"Written by":"HollandBIO","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/interna-technologies-awarded-e-2-7m-clinical-innovation-credit-from-dutch-government\/#article","isPartOf":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/interna-technologies-awarded-e-2-7m-clinical-innovation-credit-from-dutch-government\/"},"author":{"name":"HollandBIO","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/person\/48824449f08e494bb7ea02e1ff5dd6ea"},"headline":"InteRNA Technologies Awarded \u20ac 2.7M Clinical Innovation Credit from Dutch Government","datePublished":"2021-03-15T09:07:25+00:00","dateModified":"2021-03-15T09:07:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/interna-technologies-awarded-e-2-7m-clinical-innovation-credit-from-dutch-government\/"},"wordCount":254,"publisher":{"@id":"https:\/\/www.hollandbio.nl\/en\/#organization"},"articleSection":["Innovatieklimaat"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/interna-technologies-awarded-e-2-7m-clinical-innovation-credit-from-dutch-government\/","url":"https:\/\/www.hollandbio.nl\/en\/nieuws\/interna-technologies-awarded-e-2-7m-clinical-innovation-credit-from-dutch-government\/","name":"InteRNA Technologies Awarded \u20ac 2.7M Clinical Innovation Credit from Dutch Government - hollandbio","isPartOf":{"@id":"https:\/\/www.hollandbio.nl\/en\/#website"},"datePublished":"2021-03-15T09:07:25+00:00","dateModified":"2021-03-15T09:07:26+00:00","breadcrumb":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/interna-technologies-awarded-e-2-7m-clinical-innovation-credit-from-dutch-government\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.hollandbio.nl\/en\/nieuws\/interna-technologies-awarded-e-2-7m-clinical-innovation-credit-from-dutch-government\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/interna-technologies-awarded-e-2-7m-clinical-innovation-credit-from-dutch-government\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.hollandbio.nl\/en\/"},{"@type":"ListItem","position":2,"name":"InteRNA Technologies Awarded \u20ac 2.7M Clinical Innovation Credit from Dutch Government"}]},{"@type":"WebSite","@id":"https:\/\/www.hollandbio.nl\/en\/#website","url":"https:\/\/www.hollandbio.nl\/en\/","name":"hollandbio","description":"","publisher":{"@id":"https:\/\/www.hollandbio.nl\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.hollandbio.nl\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.hollandbio.nl\/en\/#organization","name":"hollandbio","url":"https:\/\/www.hollandbio.nl\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2023\/08\/HollandBIO_logo.svg","contentUrl":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2023\/08\/HollandBIO_logo.svg","width":218.664,"height":29.659,"caption":"hollandbio"},"image":{"@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/hollandbio","https:\/\/www.linkedin.com\/company\/hollandbio\/"]},{"@type":"Person","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/person\/48824449f08e494bb7ea02e1ff5dd6ea","name":"HollandBIO"}]}},"_links":{"self":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts\/19168","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/comments?post=19168"}],"version-history":[{"count":0,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts\/19168\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/media?parent=19168"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/categories?post=19168"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/tags?post=19168"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}